A machine learning model generated by a team from the European Society for Blood and Marrow Transplantation (EBMT) outperformed standard statistical models in identifying and stratifying transplant ...

I think the biggest challenge with myelofibrosis is that outside of bone marrow transplantation, which is really only a modality that offers the potential for cure to a segment of our MF patient ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain ...

I don’t really recall when I heard the news. That’s the weird thing about something traumatic, right? It completely shifts ...

Ropeg was evaluated in a phase II trial of Asian patients with pre-fibrotic or low/intermediate-risk myelofibrosis. Among 46 ...

Leukemia happens because the bone marrow makes immature cells too quickly. These cells can spread throughout the body and block healthy blood cells from growing. Myelofibrosis is a type of blood ...

The program is now moving towards the POIESIS study so that's an exciting next step that we're looking forward to and that's an active trial globally enrolling patients with myelofibrosis that are ...

Myelofibrosis is a rare blood cancer in which the bone marrow stem cells acquire a genetic defect, causing excessive production of blood cells along with a large number of inflammatory factors.

However, MorphoSys’ drug was unable to achieve the key secondary objective of reducing symptoms of myelofibrosis, a rare type of blood cancer that causes scar tissue to form in the bone marrow ...

The phase 3 trial, published this month in Nature Medicine, represents the first randomized study of JAK inhibitor-based combination therapy in treatment-naive myelofibrosis patients, signaling a ...

genetic mutations linked to aggressive myelofibrosis and poor outcomes. Erythropoiesis-stimulating agents: drugs that stimulate red blood cell production, often used to treat anemia. Patients with ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...